The IP Law Blog

JANUARY 31, 2024

In addition to the Reporting Company’s information, the CTA Report must also include the specified personal information of the Reporting Company’s ownership, each referred to as a “Beneficial Owner”. This information includes the full company name, any trade names or DBAs, principal address, and IRS taxpayer identification number.

Reporting 89

Reporting Business Ownership Registration 89

LexBlog IP

AUGUST 14, 2023

CTA defines a beneficial owner as an individual who, directly or indirectly, either (1) exercises substantial control over a Reporting Company or (2) owns or controls at least 25% of the ownership interests of a Reporting Company. It is designed to capture anyone who can make important decisions on behalf of the entity.

Business 52

Business Ownership Reporting Registration 52

The IP Law Blog

MARCH 4, 2024

In addition to the Reporting Company’s information, the CTA Report must also include the specified personal information of the Reporting Company’s ownership, each referred to as a “Beneficial Owner”. This information includes the full company name, any trade names or DBAs, principal address, and IRS taxpayer identification number.

Reporting 57

Reporting Business Ownership Government 57

LexBlog IP

JANUARY 31, 2024

Thus, we strongly encourage you to designate a trusted person to review this letter, research and understand the CTA’s application to your company, and be prepared to file the CTA Report well prior to your company’s filing deadline.

Reporting 52

Reporting Business Ownership Registration 52

LexBlog IP

OCTOBER 3, 2023

The Act, designed to thwart illicit financial activities and enhance national security, mandates thorough disclosures of beneficial ownership information. Compliance Timeline: Companies established or registered before January 1, 2024, have until January 1, 2025, to file their initial report. Who Does the CTA Impact?

Reporting 40

Reporting Business Government Ownership 40

LexBlog IP

MARCH 4, 2024

Thus, we strongly encourage you to designate a trusted person to review this letter, research and understand the CTA’s application to your company, and be prepared to file the CTA Report well prior to your company’s filing deadline.

Reporting 52

Reporting Business Ownership Government 52

Fish & Richardson Trademark & Copyright Thoughts

FEBRUARY 4, 2021

The biosimilar pathway was designed to increase competition for biologics and reduce healthcare costs. Note that FDA still has not designated any biosimilar as interchangeable to its reference product. As noted above, companies are already taking advantage of these new designations. Introduction. Federal Legislation.

Litigation 52

Litigation Settlement Marketing Marketing 52